SCHEMBL2350128

SCHEMBL2350128

Cc1n[nH]c(=O)c(-c2c(F)cc(F)cc2F)c1-c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.39
MAP3K14 Q99558 1/20 0.39
PSD A5PKW4 2/20 0.39
NOTUM Q6P988 1/20 0.37
DRD1 P21728 1/20 0.37
TYMP P19971 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
HTT P42858 2/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 2/20 0.35
PGR P06401 1/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2354063 0.90 MAPT (0.41) NOTUMDRD1TYMPMAPTMEN1
SCHEMBL2352663 0.89 MAPT (0.43) NOTUMDRD1MAPTKDM4ELMNA
SCHEMBL2351250 0.88 NPC1 (0.40) IKBKBMAP3K14NOTUMDRD1HTT
SCHEMBL2352347 0.87 ALOX12 (0.42) DRD1MAPTMAPK1KDM4ELMNA
SCHEMBL2350537 0.87 PSD (0.36) IKBKBMAP3K14PSDNOTUMDRD1
SCHEMBL2348396 0.87 IKBKB (0.44) IKBKBMAP3K14NOTUMDRD1HTT
SCHEMBL2351987 0.86 IKBKB (0.41) IKBKBMAP3K14PSDNOTUMDRD1
SCHEMBL2352300 0.86 AKT2 (0.49) DRD1TYMPKDM4ELMNAPOLB
SCHEMBL2352827 0.86 IKBKE (0.45) NOTUMTYMPGRIN2DGRIN3BGRIN1
SCHEMBL2347927 0.86 PSD (0.39) IKBKBMAP3K14PSDNOTUMDRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903436-B1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES UNIV PENNSYLVANIA (US) 2019-07-17 EP disclosed
EP-2903436-B1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES UNIV PENNSYLVANIA (US) 2019-07-17 EP disclosed
EP-2958899-B1 PROCESS FOR PRODUCING PYRIDAZINONE COMPOUND AND PRODUCTION INTERMEDIATES THEREOF SUMITOMO CHEMICAL CO (JP) 2017-10-11 EP disclosed
EP-3219207-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES The Trustees Of The University Of Pennsylvania (US) 2017-09-20 EP disclosed
EP-3219207-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES The Trustees Of The University Of Pennsylvania (US) 2017-09-20 EP disclosed
US-20170173016-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES NIH - DEITR 2017-06-22 US disclosed
US-20170173016-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES NIH - DEITR 2017-06-22 US disclosed
US-20170173016-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES NIH - DEITR 2017-06-22 US disclosed
US-9649317-B2 Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2017-05-16 US disclosed
US-9649317-B2 Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2017-05-16 US disclosed
US-20090281337-A1 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2009-11-12 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
EP-1767529-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2009-05-06 EP disclosed
EP-1767529-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2009-05-06 EP disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
EP-1767529-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2007-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173016-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES MAPT, PRNP, PSEN2 IKBKB 1767/4885MAP3K14 1624/4885PSD 2184/4885
US-20080194566-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, CYP4Z1 IKBKB 3721/4885MAP3K14 1317/4885PSD 2618/4885
US-20090281337-A1 Pyridazine compound and use thereof PLPBP, PNPO, CYP4Z1 IKBKB 3721/4885MAP3K14 1317/4885PSD 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.